The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1092
November 13, 2000
View Complete Issue         Table of Contents 2019 
Tenecteplase (TNKase) for Thrombolysis
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Tenecteplase (TNKase) for Thrombolysis
November 13, 2000 (Issue: 1092)
Tenecteplase, a recombinant variant of human tissue plasminogen activator, is now available for thrombolysis in patients with acute myocardial infarction.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Tenecteplase (TNKase) for Thrombolysis
Article code: 1092b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.